HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Combination of atiprimod and the proteasome inhibitor bortezomib induces apoptosis of mantle cell lymphoma in vitro and in vivo.

Abstract
The proteasome inhibitor bortezomib (BTZ) is known to be chemotherapeutic in relapsed or refractory mantle cell lymphoma (MCL). Atiprimod (ATI), a novel cationic amphophilic compound, has been tested in clinical trials in multiple myeloma (MM). We sought to evaluate the effect of an ATI-BTZ combination on MCL and to elucidate its therapeutic mechanisms. The ATI and BTZ combination significantly inhibited growth and induced apoptosis of both cultured MCL cell lines and freshly isolated tumor cells from patients with refractory or relapsed MCL. However, the combination yielded lower cytotoxicity in normal peripheral blood mononuclear cells (PBMC). Furthermore, ATI and BTZ induced apoptosis via two different signaling pathways. More significantly, ATI and BTZ markedly delayed tumor growth and prolonged survival in MCL-bearing NOD-SCID mice. Our results demonstrate that ATI and BTZ confer significant therapeutic effects in MCL in vitro and in vivo and should therefore be investigated in a clinical trial in patients with relapsed or refractory MCL.
AuthorsLuhong Sun, Liang Zhang, Jianfei Qian, Jing Yang, Qing Yi, Wenli Dong, Michael Wang
JournalLeukemia research (Leuk Res) Vol. 36 Issue 3 Pg. 363-8 (Mar 2012) ISSN: 1873-5835 [Electronic] England
PMID22000823 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2011. Published by Elsevier Ltd.
Chemical References
  • Antineoplastic Agents
  • Apoptosis Inducing Factor
  • Boronic Acids
  • Pyrazines
  • Spiro Compounds
  • azaspirane
  • Bortezomib
Topics
  • Animals
  • Antineoplastic Agents (therapeutic use)
  • Apoptosis (drug effects)
  • Apoptosis Inducing Factor (metabolism)
  • Blotting, Western
  • Boronic Acids (therapeutic use)
  • Bortezomib
  • Cell Line, Tumor
  • Cell Proliferation (drug effects)
  • Drug Synergism
  • Humans
  • In Vitro Techniques
  • Leukocytes, Mononuclear (drug effects, metabolism, pathology)
  • Lymphoma, Mantle-Cell (drug therapy, mortality, pathology)
  • Male
  • Mice
  • Mice, Inbred NOD
  • Mice, SCID
  • Pyrazines (therapeutic use)
  • Spiro Compounds (therapeutic use)
  • Survival Rate

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: